Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 72

Sort by

Sort Order Select

Journal Articles

Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial

Blood (2018) 132 (4): 393–404.

https://doi.org/10.1182/blood-2016-09-739086

Published: 2018

Includes: Supplemental data

Journal Articles

Final Evaluation of Randomized CML-Study IV: 10-Year Survival and Evolution of Terminal Phase

Rüdiger Hehlmann, MD, Michael Lauseker, PhD, Susanne Saussele, MD, Markus Pfirrmann, Stefan W. Krause, MD, Hans-Jochem Kolb, MD, Andreas Neubauer, MD, Dieter K. Hossfeld, Christoph Nerl, MD, Alois Gratwohl, MD, Gabriela M. Baerlocher, Dominik Heim, MD, Tim Henrik Bruemmendorf, Alice Fabarius, PhD, Claudia Haferlach, MD, Brigitte Schlegelberger, MD PhD, Martin C. Müller, MD, Sabine Jeromin, PhD, Ulrike Proetel, PhD, Katharina Kohlbrenner, PhD, Astghik Voskanyan, PhD, Sébastien Rinaldetti, Wolfgang Seifarth, PhD, Birgit Spiess, Leopold Balleisen, MD, Maria E Goebeler, MD, Mathias Hänel, MD, Anthony D. Ho, MD, J Dengler, C Falge, Lothar Kanz, MD, Claus-Henning Köhne, MD, PhD, Andreas Burchert, MD, Michael Kneba, MD PhD, Frank Stegelmann, MD, C Köhne, Hans-Walter Lindemann, C Waller, Michael Pfreundschuh, MD, Karsten Spiekermann, Wolfgang E Berdel, MD, L Müller, Matthias Edinger, MD, Jiri Mayer, Prof, MD SCs, Dietrich W Beelen, MD PhD, Martin Bentz, MD, Hartmut Link, MDPhD, Bernd Hertenstein, MD, R Fuchs, Martin Wernli, MD, F Schlegel, Rudolph Schlag, M de Wit, Lorenz Trümper, MD, H Hebarth, M Hahn, Jörg Thomalla, MD, Christof Scheid, MD, Philippe Schafhausen, MD, Walter Verbeek, MD, Michael J. Eckart, MD, Winfried Gassmann, MD PhD, Antonio Pezzutto, MD, Michael Schenk, Peter Brossart, MD, Thomas Geer, MD, Stephan Bildat, E Schäfer, Andreas Hochhaus, MD, Joerg Hasford

Blood (2017) 130 (Supplement 1): 897.

https://doi.org/10.1182/blood.V130.Suppl_1.897.897

Published: 2017

Journal Articles

Sample Exchange to Standardize Molecular Monitoring for CML: The EUTOS Experience

Martin C. Müller, MD, Christian Dietz, PhD, Giuseppe Saglio, MD PhD, Francois-Xavier Mahon, MD PhD, Fabrizio Pane, MD, Andreas Hochhaus, MD, Nicholas C.P. Cross, PhD

Blood (2017) 130 (Supplement 1): 2874.

https://doi.org/10.1182/blood.V130.Suppl_1.2874.2874

Published: 2017

Journal Articles

No Differences in Molecular Relapse-Free Survival after Stopping Imatinib Treatment of Chronic Myeloid Leukemia Between Patients with Prior 4.5 Log Reduction (MR4.5) but Detectable and Patients with Undetectable Disease in the EURO-SKI Trial

Blood (2016) 128 (22): 789.

https://doi.org/10.1182/blood.V128.22.789.789

Published: 2016

Journal Articles

Treatment-Free Remission (TFR) in Patients with Chronic Phase Chronic Myeloid Leukemia (CML-CP) and in Stable Deep Molecular Response (DMR) to Dasatinib - the Dasfree Study

Neil P. Shah, MD PhD, Ronald Paquette, MD, Martin C. Müller, MD, Susanne Saussele, MD, Valentin Garcìa-Gutiérrez, MD, Antonio Jiménez-Velasco, MD, Franck-Emmanuel Nicolini, MD PhD, Michael J. Mauro, MD, Francois-Xavier Mahon, MD PhD, Delphine Rea, MD PhD, Patricia Martin-Regueira, MD, Milayna Subar, MD, Li Li, PhD, Jeffrey H. Lipton, MD PhD

Blood (2016) 128 (22): 1895.

https://doi.org/10.1182/blood.V128.22.1895.1895

Published: 2016

Journal Articles

Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients

Blood (2016) 127 (6): 703–712.

https://doi.org/10.1182/blood-2015-08-660977

Published: 2016

Includes: Supplemental data

Journal Articles

Germline RBBP6 mutations in familial myeloproliferative neoplasms

Blood (2016) 127 (3): 362–365.

https://doi.org/10.1182/blood-2015-09-668673

Published: 2016

Includes: Supplemental data

Journal Articles

Quantification of BCR-ABL with Digital PCR Results in a Significantly Lower Rate of Deep Molecular Responses When Compared to RT-qPCR in CML Patients Treated in the ENEST1st Trial

Georg-Nikolaus Franke, MD, Jacqueline Maier, PhD, Kathrin Wildenberger, Michael Cross, PhD, Oliver Frank, PhD, Frank Giles, MDMB, Andreas Hochhaus, MD, Christian T. Dietz, PhD, Martin C. Müller, Dietger Niederwieser, MD, Thoralf Lange, MD

Blood (2015) 126 (23): 135.

https://doi.org/10.1182/blood.V126.23.135.135

Published: 2015

Journal Articles

Frequency of CTLA-4 Receptor Ligand (CD86, B7.2) -Positive Plasmacytoid Dendritic Cells Predicts Risk of Disease Recurrence after Tyrosine-Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Results from a Prospective Substudy of the Euroski Trial

Blood (2015) 126 (23): 599.

https://doi.org/10.1182/blood.V126.23.599.599

Published: 2015

Journal Articles

Evaluation of the Benefit/Risk Profile of Ponatinib in CP-CML Patients over Time: 4-Year Follow-up of the Phase 2 PACE Study

Blood (2015) 126 (23): 5142.

https://doi.org/10.1182/blood.V126.23.5142.5142

Published: 2015

Journal Articles

Mature, Adaptive-like CD56 DIM NK Cells in Chronic Myeloid Leukemia Patients in Treatment Free Remission

Blood (2015) 126 (23): 343.

https://doi.org/10.1182/blood.V126.23.343.343

Published: 2015

Journal Articles

Impact of Age on Efficacy and Toxicity of Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis

Blood (2015) 126 (23): 479.

https://doi.org/10.1182/blood.V126.23.479.479

Published: 2015

Journal Articles

A Multi-Institutional Retrospective Analysis of Tyrosine Kinase Inhibitor (TKI) Clinical and Preclinical Efficacy According to BCR-ABL Mutation Status in CP-CML Patients

Victor M. Rivera, Susan Branford, Franck E. Nicolini, Justin R. Pritchard, Joseph M. Gozgit, Wolfgang Kern, MD, Dragana Milojkovic, Simone Claudiani, Martin C. Muller, Srinivas K Tantravahi, Michael W. Deininger, Michael Heinrich, Simona Soverini, Michele Baccarani, Jerald P. Radich, Elias Jabbour, Jorge E. Cortes, Gabriel Etienne, Torsten Haferlach

Blood (2015) 126 (23): 2790.

https://doi.org/10.1182/blood.V126.23.2790.2790

Published: 2015

Journal Articles

Molecular Response with Nilotinib in Patients with Philadelphia Negative (Ph-) Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis

Blood (2015) 126 (23): 4054.

https://doi.org/10.1182/blood.V126.23.4054.4054

Published: 2015

Journal Articles

Efficacy and Safety of Ponatinib in CP-CML Patients By Number of Prior Tyrosine Kinase Inhibitors: 4-Year Follow-up of the Phase 2 PACE Trial

Blood (2015) 126 (23): 4025.

https://doi.org/10.1182/blood.V126.23.4025.4025

Published: 2015

Journal Articles

Major Route Additional Chromosomal Aberrations (ACA) Precede Increase of Blasts in CML: An Analysis of the German CML-Studies III and IIIA

Christian T. Dietz, PhD, Alice Charlotte Fabarius, PhD, Michael Lauseker, PhD, Susanne Saussele, Lida Kalmanti, Sébastien Rinaldetti, Claudia Haferlach, MD, Brigitte Schlegelberger, MD PhD, Martine Jotterand, Alois Gratwohl, Axel R. Zander, Professor, Nicolaus Kröger, Dietrich W. Beelen, MD, Jürgen Novotny, Christoph Nerl, Christof Scheid, MD PhD, Karsten Spiekermann, Jiri Mayer, MD, Herbert G. Sayer, Christiane Falge, Donald Bunjes, MD, Hartmut Döhner, Prof. Dr., Arnold Ganser, Peter Brossart, MD, Rainer Schwerdtfeger, Herrad Baumann, Rolf Kuse, Hans Walter Lindemann, MD, Matthias Bormann, Bernd Hertenstein, MD, Gabriela M. Baerlocher, Carlo Aul, MD, Peter Staib, Matthias Edinger, MD, Michael Schatz, Axel A Fauser, Renate Arnold, MD, Dieter K. Hossfeld, MD, Hans-Jochem Kolb, Susanne Schnittger, PhD, Martin C. Müller, MD, Andreas Reiter, MD, Andreas Hochhaus, MD, Markus Pfirrmann, Joerg Hasford, Michele Baccarani, Ruediger Hehlmann, MD

Blood (2015) 126 (23): 1581.

https://doi.org/10.1182/blood.V126.23.1581.1581

Published: 2015

Journal Articles

Health-Related Quality of Life Impairment in Patients with Chronic Myeloid Leukemia: Results of a German Cross-Sectional Study of Patients Registered in Prospective, Controlled Clinical Trials

Blood (2015) 126 (23): 2773.

https://doi.org/10.1182/blood.V126.23.2773.2773

Published: 2015

Journal Articles

Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV

Blood (2015) 126 (1): 42–49.

https://doi.org/10.1182/blood-2015-01-617993

Published: 2015

Includes: Supplemental data

Journal Articles

Early Disease Relapse after Tyrosine Kinase Inhibitor Treatment Discontinuation in CML Is Related Both to Low Number and Impaired Function of NK-Cells

Blood (2014) 124 (21): 812.

https://doi.org/10.1182/blood.V124.21.812.812

Published: 2014

Journal Articles

Prognostic Value of Multi-Drug Resistance 1 Gene (MDR1) Expression in Newly Diagnosed Patients with Chronic Myeloid Leukemia on Nilotinib Treatment—a Subanalysis of the ENEST1st Study

Christian Dietz, PhD, Michael Lauseker, PhD, Benjamin Hanfstein, MD, Philippe Rousselot, MD, Thoralf Lange, MD, Jacqueline Maier, PhD, Letizia Foroni, Gareth Gerrard, Rodica Talmaci, PhD, Jeroen JWM Janssen, MD, Oliver Frank, PhD, Susanne Saussele, MD, Frank Giles, MDMB, Andreas Hochhaus, MD, Martin C. Müller, MD

Blood (2014) 124 (21): 3144.

https://doi.org/10.1182/blood.V124.21.3144.3144

Published: 2014

NARROW

Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial

Final Evaluation of Randomized CML-Study IV: 10-Year Survival and Evolution of Terminal Phase

Sample Exchange to Standardize Molecular Monitoring for CML: The EUTOS Experience

No Differences in Molecular Relapse-Free Survival after Stopping Imatinib Treatment of Chronic Myeloid Leukemia Between Patients with Prior 4.5 Log Reduction (MR4.5) but Detectable and Patients with Undetectable Disease in the EURO-SKI Trial

Treatment-Free Remission (TFR) in Patients with Chronic Phase Chronic Myeloid Leukemia (CML-CP) and in Stable Deep Molecular Response (DMR) to Dasatinib - the Dasfree Study

Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients

Germline RBBP6 mutations in familial myeloproliferative neoplasms

Quantification of BCR-ABL with Digital PCR Results in a Significantly Lower Rate of Deep Molecular Responses When Compared to RT-qPCR in CML Patients Treated in the ENEST1st Trial

Frequency of CTLA-4 Receptor Ligand (CD86, B7.2) -Positive Plasmacytoid Dendritic Cells Predicts Risk of Disease Recurrence after Tyrosine-Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Results from a Prospective Substudy of the Euroski Trial

Evaluation of the Benefit/Risk Profile of Ponatinib in CP-CML Patients over Time: 4-Year Follow-up of the Phase 2 PACE Study

Mature, Adaptive-like CD56 DIM NK Cells in Chronic Myeloid Leukemia Patients in Treatment Free Remission

Impact of Age on Efficacy and Toxicity of Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis

A Multi-Institutional Retrospective Analysis of Tyrosine Kinase Inhibitor (TKI) Clinical and Preclinical Efficacy According to BCR-ABL Mutation Status in CP-CML Patients

Molecular Response with Nilotinib in Patients with Philadelphia Negative (Ph-) Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis

Efficacy and Safety of Ponatinib in CP-CML Patients By Number of Prior Tyrosine Kinase Inhibitors: 4-Year Follow-up of the Phase 2 PACE Trial

Major Route Additional Chromosomal Aberrations (ACA) Precede Increase of Blasts in CML: An Analysis of the German CML-Studies III and IIIA

Health-Related Quality of Life Impairment in Patients with Chronic Myeloid Leukemia: Results of a German Cross-Sectional Study of Patients Registered in Prospective, Controlled Clinical Trials

Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV

Early Disease Relapse after Tyrosine Kinase Inhibitor Treatment Discontinuation in CML Is Related Both to Low Number and Impaired Function of NK-Cells

Prognostic Value of Multi-Drug Resistance 1 Gene (MDR1) Expression in Newly Diagnosed Patients with Chronic Myeloid Leukemia on Nilotinib Treatment—a Subanalysis of the ENEST1st Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only